28. Kron A, Alidousty C, Scheffler M, et al. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol. 2018;29(10):2068–2075. doi:10.1093/annonc/mdy333 29. Christopou...
1. Dearden S, Stevens J, Wu YL, et al. Mutation incidence and coincidence in non small-cell lung cancer: metaanalyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24:2371-6. 2. Koivunen JP, Mermel C...
与克唑替尼相比,未经治疗的ALK阳性晚期NSCLC患者获得了更大的临床益处,具有更高的ORR和潜在的更长的PFS,这一临床获益效果与EML4::ALK变体或ALK突变、TP53突变或旁路耐药改变无关。 SCI 19 August 2023 Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced non-small cell lung cancer ...
Real-World Treatment Patterns and Effectiveness of Subsequent Treatments Following First-line (1L) Brigatinib for Patients with Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) from ALTA-1L ALTA-1L 中ALK+NSCLC 患者一线接受布格替尼治疗后后续治疗的真实世界治疗模式和有效...
非小细胞肺癌与ALK、EGFR、HER2等抑制剂关系 - MCE 全球每年大约有 160 万人死于肺癌。根据细胞来源，约 80-85％是非小细胞肺癌 (NSCLC)。在组织学上，NSCLC 有几种亚型，包括肺腺癌 (LUAD)、肺鳞状细胞癌 (LUSC)、大细胞癌等。基因分型研究已经揭示了 NSCLC 各种亚型的遗传/分子异常，这些驱动致癌突变使癌...
3月12日,贝达药业发布公告称,恩沙替尼用于间变性淋巴瘤激酶(ALK)阳性局部晚期或转移性非小细胞肺癌(NSCLC)患者一线治疗的新药上市申请(NDA)已获得美国食品药品监督管理局(FDA)受理。目标日期已确定为2024年12月28日。 该申请得到了3期 eXalt3研究(NCT02767804)数据的支持,eXalt3的研究结果于2021年9月发表在《JAMA...
飞朔致力于为肿瘤个体化精准医学检测提供最具创新性的产品和服务,并持续更新现有产品。 参考文献 Long-term survival of an ALK fusion lung adenocarcinoma patient with high mutation burden and microsatellite instability high: a case report[J]. Anticancer Drugs. 2025 Feb 6....
2. Solomon BJ, Kim DW, Wu YL, et al. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer[J]. J Clin Oncol, 2018, 36(22):2251-2258.
[4]Hsu KH, Tseng JS, et al.PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. Sci Rep 2022 Jun 13;12(1) [5] Yoshimura A , Yamada T , Okuma Y , et al. Impact of tumor programmed death ...
4. Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study[J]. Ann Oncol, 2020, 31(8):1056-1064. ...